CD22 expression (target of inotuzumab ozogamicin)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD22-EXPRESSION |
|---|---|
| Type | Biomarker |
| Aliases | CD22 expressionЕкспресія CD22 (мішень інотузумабу озогаміцину) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-INOVATE-KANTARJIAN-2016 SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodFlow cytometry on PB/BM blasts OR IHC on FFPE biopsy (anti-CD22) Unitscategorical (positive ≥20% blasts | negative); semi-quantitative % |
| Related biomarkers | None declared |
Notes
CD22+ status (≥20% of blasts/lymphoma cells expressing CD22 by flow or IHC) is the standard eligibility threshold for inotuzumab ozogamicin (anti-CD22 calicheamicin ADC) — INO-VATE used flow ≥20% of blasts. Cross-disease relevance: - **B-ALL** (~90%+): CD22+ on virtually all B-ALL — required for inotuzumab in R/R B-ALL (INO-VATE 2L+; CR/CRi 81% vs 29% chemo). Also gates moxetumomab (HCL) and emerging CD22 CAR-T trials. - **B-cell NHL** (variable): CD22+ in CLL, MCL, FL, DLBCL — quantitative threshold matters for ADC dosing rationale; qualitative positive for diagnostic panel use. - **HCL**: CD22+ universally (target of moxetumomab). Quantitative measurement matters: weak / partial CD22 expression predicts inferior ADC response. VOD/SOS risk post-allo-HCT (~14% in INO-VATE) — pre-transplant inotuzumab dose limit. `ihc_no_variant` skip reason — protein expression target, not variant lookup.
Used By
No reverse references found in the YAML corpus.